ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Sep 22, 2026
DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC
Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence
DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.
The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.
Why this award matters
NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.
"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."
Patrick Smale, Co-founder and Chief Executive Officer
"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."
Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator
"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."
Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member
The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.
Important regulatory context
ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.
NIH funding acknowledgment
Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Media contact
Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761
Photos: (Click photo to enlarge)
Source: ClearSight Therapeutics, Inc.
Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source
Press release distribution by PRLog
More News
Malicious npm Package Poses as Twilio Bug-Bounty Probe, Can Exfiltrate Credentials
Cybersecurity researchers have disclosed details of a malicious npm package named "tw-pkgprobe-7731" that masquerades as a security tool targeting developers integrating Twilio into their applications, while stealthily attempting to harvest sensitive data. The package, named "tw-pkgprobe-7731," was first uploaded to the npm registry in mid-August 2026 by an npm account named "twdepprobe7731."
Microsoft Takes Down EvilTokens Device-Code Phishing Service Tied to 12,000 Inbox Compromises
Microsoft on Tuesday announced the takedown of the EvilTokens device code phishing service that it said used artificial intelligence (AI) "at every step of the attack chain." The action, carried out with authorization from the U.S. District Court for the Eastern District of Virginia, involved the efforts of Health-ISAC, alongside Cloudflare, Coinbase, OpenAI, Railway, SpyCloud, The Shadowserver
Critical Bifrost AI Gateway Flaw Lets Attackers Run Commands Without Credentials
A critical vulnerability in Bifrost, an open-source AI gateway that routes requests to more than 20 LLM providers, allows an unauthenticated attacker to run arbitrary commands on the gateway server with a single HTTP request. The flaw, tracked as CVE-2026-90898 (CVSS score: 9.8), affects all versions of the Bifrost HTTP transport before 2.1.0 when management authentication is
The Big Threat Has Been Climate Change. Now Comes A.I.
Both are human-caused, both are frightening, and one of them has raced to the forefront of the global conversation.
Sea turtle laying eggs at Huntington Beach is first known instance of nesting on West Coast
At least one olive ridley sea turtle has laid its eggs on the sand in Huntington Beach.
Researcher Drops BigDiskBuster Zero-Day PoC That Blocks Microsoft Defender Updates
A zero-day proof-of-concept tool that stops Microsoft Defender from installing platform and signature updates by filling all available disk space was published on GitHub on September 19. The tool, called BigDiskBuster, has no patch, no CVE, and no Microsoft advisory. Its author, Abdelhamid Naceri, is a former Microsoft security researcher whose earlier Defender exploits were used in
C.T.E. Can’t Be Detected in the Living. New Brain Research Offers Hope.
Scientists are developing imaging techniques and blood tests that one day may enable doctors to identify the disease definitively in living patients.
Mathematics Isn’t Just a Game to Let A.I. Solve. History Shows Why.
In our field of applied mathematics, the long, human process of trial and error — not just the solutions themselves — is often what has led to progress.
Man vs robot: Influencer takes on 6ft humanoid in a terrifying cage fight - and it doesn't end well for him
It might sound like the plot of a bonkers sci-fi film, but the world has now witnessed the very first human vs robot boxing match.
Gen Z are in a sex RECESSION, study reveals - with a fifth reporting they've never had a partner
Despite being the generation that grew up with Tinder, Hinge and Bumble at their fingertips, a study has revealed Gen Z is in a sex recession.
Call of Duty's Activision to make next Halo game as Xbox cuts more jobs
The news comes as part of a "reset" announced by Xbox in July, with 3,600 planned job losses overall.
China’s Hygon moves beyond data centres with embedded processors for robotics, edge AI
Chinese chipmaker Hygon Information Technology on Tuesday launched a suite of central processing units (CPUs) for robotics and industrial edge devices, expanding beyond cloud computing and into the fast-growing market for physical artificial intelligence. The firm unveiled its Hygon 1000 series processors, designed to be embedded into physical devices in industrial automation systems such as robotics and factory controllers, enabling computing and graphics processing to be handled locally. Built...
Recommended
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.